The global market for diabetes management apps is expected to surge, driven by device integration, AI analytics, and reimbursement models, transforming how patients and clinicians manage blood sugar outside of clinics.
The market for diabetes management apps is expanding quickly as software moves from simple blood-sugar logbooks to connected care platforms that pull in data from glucose monitors, pumps, smart pens and coaching tools. DataM Intelligence, in a report published through openPR, said the category was worth $1.71 billion in 2025 and could reach $15.53 billion by 2035, a forecast that underscores how digital diabetes care is being reshaped around device integration, predictive analytics and clinician access.
That upbeat outlook is not universal. Other market studies point to a much smaller opportunity, although they still describe the same broad shift towards connected monitoring and personalised support. DataM Intelligence’s own research page puts the market at $9.90 billion by 2033, while Grand View Research estimates $3.1 billion by 2030 and Market.us sees $4.8 billion by 2034. The differences largely reflect varying definitions of the market, but all of the reports agree that apps are becoming more useful when they reduce manual entry and turn data into action.
The commercial case is increasingly tied to features that make diabetes management easier between clinic visits. Predictive tools, medication reminders, nutrition tracking and secure data-sharing are now central selling points, especially as apps are expected to support not just consumers but also providers and payers. DataM Intelligence said AI-based predictive analytics accounted for a significant share of application revenue in 2025, reflecting demand for forecasting, pattern detection and coaching that can guide day-to-day decisions.
Reimbursement is another important driver. The report said paid subscriptions and licensed programmes made up most of revenue in 2025, a sign that health plans, employers and care providers are playing a larger role in purchasing digital diabetes tools. That shift favours platforms that can show engagement, security and measurable outcomes rather than those that rely only on app-store downloads. Home-based use also remains the biggest deployment model, which is unsurprising given that most diabetes decisions happen outside appointments.
The report highlighted companies such as Glooko, Welldoc, Dexcom and Roche Diabetes Care as examples of the sector’s move towards integrated care platforms. Their products combine device data, coaching and clinician-facing functions, while also extending into broader cardiometabolic management, including weight and nutrition support. DataM Intelligence said North America accounted for 42% of global revenue in 2025, while Asia-Pacific is expected to grow rapidly as Android-first design, multilingual content and lower-cost access widen adoption.
Still, the report cautioned that market growth will depend on more than feature lists. Interoperability, cybersecurity, privacy and user engagement remain barriers, and software providers must prove their systems can fit into clinical workflows without adding burden. As diabetes apps become more closely linked to connected devices and reimbursed care, the winners are likely to be those that can combine reliable data capture with practical support for patients and providers alike.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
